Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease characterized by persistent joint synovial inflammation and swelling, leading to cartilage damage and bone erosion. This retrospective, longitudinal study is to evaluate the treatment patterns of biologic-naïve RA patients receivin...
Saved in:
Main Authors: | Ko-Jen Li (Author), Chia-Li Chang (Author), Chih-Yi Hsin (Author), Chao-Hsiun Tang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020) -
Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database
by: Wan Xiong, et al.
Published: (2024) -
Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
by: Yinan Huang, et al.
Published: (2023) -
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
by: Irma Convertino, et al.
Published: (2023) -
Use of YAKVINUS® (tofacitinib) for the treatment of rheumatoid arthritis
by: article Editorial
Published: (2018)